Yahoo
    Swiss - Delayed Quote CHF

    Molecular Partners AG (MOLN.SW)

    2.6800 -0.1000 (-3.60%)
    As of 10:35:51 AM GMT+1. Market Open.
    Loading Chart for MOLN.SW
    Chart Range Bar
    Interval:
    In partnership with ChartIQ

    Recent News

    Molecular Partners and Orano Med Announce First Patients Dosed in Phase 1/2a Trial of DLL3 Radio-DARPin MP0712

    Molecular Partners and Orano Med Announce First Patients Dosed in Phase 1/2a Trial of DLL3 Radio-DARPin MP0712
    GlobeNewswire 4mo ago
    Molecular Partners Holds Presentations at ASCO and SNMMI 2026 on DLL3-Targeting Radio-DARPin MP0712, Now Dosing Patients in Phase 1

    Molecular Partners Holds Presentations at ASCO and SNMMI 2026 on DLL3-Targeting Radio-DARPin MP0712, Now Dosing Patients in Phase 1
    GlobeNewswire 5mo ago
    Molecular Partners to Present at TD Cowen’s 7th Annual Oncology Innovation Summit

    Molecular Partners to Present at TD Cowen’s 7th Annual Oncology Innovation Summit
    GlobeNewswire 5mo ago
    Molecular Partners Reports Financial Results and Highlights for Q1 2026, with Clinical Studies Initiated on MP0712 and MP0317

    Molecular Partners Reports Financial Results and Highlights for Q1 2026, with Clinical Studies Initiated on MP0712 and MP0317
    GlobeNewswire 5mo ago
    Molecular Partners to hold oral presentations on DLL3-targeting Radio-DARPin candidate MP0712 at multiple upcoming scientific conferences

    Molecular Partners to hold oral presentations on DLL3-targeting Radio-DARPin candidate MP0712 at multiple upcoming scientific conferences
    GlobeNewswire 5mo ago
    Molecular Partners publishes Phase 1 MP0317 data in Nature Cancer demonstrating tumor-localized CD40 activation and tumor microenvironment remodeling

    Molecular Partners publishes Phase 1 MP0317 data in Nature Cancer demonstrating tumor-localized CD40 activation and tumor microenvironment remodeling
    GlobeNewswire 6mo ago
    Molecular Partners presents three posters at AACR 2026, with new preclinical data for first Switch-DARPin T cell engager MP0632 and DLL3 Radio-DARPin MP0712

    Molecular Partners presents three posters at AACR 2026, with new preclinical data for first Switch-DARPin T cell engager MP0632 and DLL3 Radio-DARPin MP0712
    GlobeNewswire 6mo ago
    Eckert & Ziegler SE (XTER:EUZ) Q1 2026 Earnings Call Highlights: Strong Medical Division ...

    Eckert & Ziegler SE (XTER:EUZ) Q1 2026 Earnings Call Highlights: Strong Medical Division ...
    GuruFocus.com 5mo ago
    Molecular Partners Reports Q3 2026 Financial Results, Deepens Focus on Targeted Radiotherapy

    Molecular Partners Reports Q3 2026 Financial Results, Deepens Focus on Targeted Radiotherapy
    GlobeNewswire 5d ago
    Molecular Partners Nominates MP0730 as Next Candidate in Expanding Pipeline of Radiotherapeutics, Targeting CD70

    Molecular Partners Nominates MP0730 as Next Candidate in Expanding Pipeline of Radiotherapeutics, Targeting CD70
    GlobeNewswire 12d ago
    Molecular Partners Reports H1 2026 Financial Results and Corporate Highlights: DLL3 Radiotherapy MP0712 Successfully Advancing to Higher Dose Level in Phase 1/2a Study

    Molecular Partners Reports H1 2026 Financial Results and Corporate Highlights: DLL3 Radiotherapy MP0712 Successfully Advancing to Higher Dose Level in Phase 1/2a Study
    GlobeNewswire 2mo ago

    Related Tickers

    Mobilize your Website
    View Site in Mobile | Classic
    Share by: